AptaPharma Inc.

Form 483 issued September 25, 2019 · Pennsauken, New Jersey

Inspection
Sep 9 – Sep 25, 2019
Investigator
Nancy M. Espinal
Observations
2
Pages
2
FEI number
3010164738

In short: On September 25, 2019, FDA issued a Form 483 with 2 observations to AptaPharma Inc. in Pennsauken, New Jersey (FEI 3010164738) after an inspection that ran Sep 9 – Sep 25, 2019. The investigator was Nancy M. Espinal. Most observations concern laboratory controls and facilities & equipment; the most-cited regulation is 21 CFR 211.160 (general requirements).

At a glance

Laboratory controls and facilities & equipment account for 2 of 2 observations.

Laboratory controls1
Facilities & equipment1

Most cited: 21 CFR 211.160 (1×) · 211.63 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Established specifications are not…

  2. 02

    Lack of capacity to…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at AptaPharma Inc.?

FDA listed 2 observations on this Form 483, mostly about laboratory controls and facilities & equipment. The most-cited regulation is 21 CFR 211.160 (general requirements). The opening words of each observation are shown on this page.

Who inspected AptaPharma Inc.?

Nancy M. Espinal is named on this Form 483, for the inspection of Sep 9 – Sep 25, 2019. Each investigator has a profile showing what they cite most.

When was AptaPharma Inc. inspected by FDA?

The inspection ran Sep 9 – Sep 25, 2019, and the Form 483 is dated September 25, 2019.

How do I get the full Form 483 for AptaPharma Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free